Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b

V Ramirez-Ramirez, M A Macias-Islas, G G Ortiz, F Pacheco-Moises, E D Torres-Sanchez, T E Sorto-Gomez, J A Cruz-Ramos, G Orozco-Aviña, A J Celis de la Rosa, V Ramirez-Ramirez, M A Macias-Islas, G G Ortiz, F Pacheco-Moises, E D Torres-Sanchez, T E Sorto-Gomez, J A Cruz-Ramos, G Orozco-Aviña, A J Celis de la Rosa

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease, which leads to focal plaques of demyelination and tissue injury in the central nervous system. Oxidative stress is also thought to promote tissue damage in multiple sclerosis. Current research findings suggest that omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapenta-enoic acid (EPA) and docosahexaenoic acid (DHA) contained in fish oil may have anti-inflammatory, antioxidant, and neuroprotective effects. The aim of the present work was to evaluate the efficacy of fish oil supplementation on serum proinflammatory cytokine levels, oxidative stress markers, and disease progression in MS. 50 patients with relapsing-remitting MS were enrolled. The experimental group received orally 4 g/day of fish oil for 12 months. The primary outcome was serum TNF α levels; secondary outcomes were IL-1 β 1b, IL-6, nitric oxide catabolites, lipoperoxides, progression on the expanded disability status scale (EDSS), and annualized relapses rate (ARR). Fish oil treatment decreased the serum levels of TNF α , IL-1 β , IL-6, and nitric oxide metabolites compared with placebo group (P ≤ 0.001). There was no significant difference in serum lipoperoxide levels during the study. No differences in EDSS and ARR were found.

Conclusion: Fish oil supplementation is highly effective in reducing the levels of cytokines and nitric oxide catabolites in patients with relapsing-remitting MS.

Figures

Figure 1
Figure 1
Trial profile.
Figure 2
Figure 2
Outcomes at each timepoint in both groups. Data expressed in mean and standard deviation (SD), Mann-Whitney U test. Months (m), *P ≤ 0.05, **P ≤ 0.001.

References

    1. Nakahara J, Maeda M, Aiso S, Suzuki N. Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy. Clinical Reviews in Allergy and Immunology. 2012;42(1):26–34.
    1. Riccio P. The molecular basis of nutritional intervention in multiple sclerosis: a narrative review. Complementary Therapies in Medicine. 2011;19(4):228–237.
    1. Bazan NG, Musto AEM, Knott EJK. Endogenous signaling by omega-3 docosahexaenoic acid-derived mediators sustains homeostatic synaptic and circuitry integrity. Molecular Neurobiology. 2011;44(3):216–222.
    1. Selmi C, Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. Autoimmunity Reviews. 2010;9(5):A267–A270.
    1. Gallai V, Sarchielli P, Trequattrini A, et al. Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. Journal of Neuroimmunology. 1995;56(2):143–153.
    1. Torkildsen O, Wergeland S, Bakke S, et al. omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Archives of Neurology. 2012;69:1044–1051.
    1. Mehta LR, Dworkin RH, Schwid SR. Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nature Clinical Practice Neurology. 2009;5(2):82–92.
    1. Farooqui AA, Horrocks LA, Farooqui T. Modulation of inflammation in brain: a matter of fat. Journal of Neurochemistry. 2007;101(3):577–599.
    1. Calder PC. n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. American Journal of Clinical Nutrition. 2006;83(6):1505S–1519S.
    1. Ortiz GG, Macías-Islas MÁ, Pacheco-Moisés FP, et al. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Disease Markers. 2009;26(1):35–39.
    1. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. The New England Journal of Medicine. 1991;325(7):467–472.
    1. Probert L, Eugster H, Akassoglu K, et al. TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain. 2000;123(10):2005–2019.
    1. Christophi GP, Christophi JA, Gruber RC, et al. Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients. Journal of the Neurological Sciences. 2011;307(1-2):41–45.
    1. Swank RL. Treatment of multiple sclerosis with low-fat diet; results of five and one-half years’ experience. American Medical Association Archives of Neurology and Psychiatry. 1955;73(6):631–644.
    1. Swank RL. Treatment of multiple sclerosis with low-fat diet: result of seven years’ experience. Annals of internal medicine. 1956;45(5):812–824.
    1. Swank RL. Multiple sclerosis: twenty years on low fat diet. Archives of Neurology. 1970;23(5):460–474.
    1. Swank RL, Goodwin J. Review of MS patient survival on a Swank low saturated fat diet. Nutrition. 2003;19(2):161–162.
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology. 1983;33(11):1444–1452.
    1. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Annals of Neurology. 2005;58(6):840–846.
    1. Edwards P. Questionnaires in clinical trials: guidelines for optimal design and administration. Trials. 2010;11(article 2)
    1. Esterbauer H, Schaur RJ, Zollner H. Chemistry and Biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biology and Medicine. 1991;11(1):81–128.
    1. Salvati S, Natali F, Attorri L, et al. Eicosapentaenoic acid stimulates the expression of myelin proteins in rat brain. Journal of Neuroscience Research. 2008;86(4):776–784.
    1. Harris MA, Hansen RA, Vidsudhiphan P, et al. Effects of conjugated linoleic acids and docosahexaenoic acid on rat liver and reproductive tissue fatty acids, prostaglandins and matrix metalloproteinase production. Prostaglandins Leukotrienes and Essential Fatty Acids. 2001;65(1):23–29.
    1. Harbige LS, Yeatman N, Amor S, Crawford MA. Prevention of experimental autoimmune encephalomyelitis in Lewis rats by a novel fungal source of γ-linolenic acid. British Journal of Nutrition. 1995;74(5):701–715.
    1. Harbige LS, Sharief MK. Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis. British Journal of Nutrition. 2007;98(supplement 1):S46–S53.
    1. Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. The effect on human tumor necrosis factor α and interleukin 1β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. American Journal of Clinical Nutrition. 1996;63(1):116–122.
    1. Bertolotto A, Malucchi S, Capobianco M, et al. Quantitative PCR reveals increased levels of tumor necrosis factor-α mRNA in peripheral blood mononuclear cells of multiple sclerosis patients during relapses. Journal of Interferon and Cytokine Research. 1999;19(6):575–581.
    1. Scales WE, Chensue SW, Otterness I, Kunkel SL. Regulation of monokine gene expression: prostaglandin E2 suppresses tumor necrosis factor but not interleukin-1α or β-mRNA and cell-associated bioactivity. Journal of Leukocyte Biology. 1989;45(5):416–421.
    1. Kunkel SL, Chensue SW. Arachidonic acid metabolites regulate interleukin-1 production. Biochemical and Biophysical Research Communications. 1985;128(2):892–897.
    1. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. The New England Journal of Medicine. 1989;320(5):265–271.
    1. DeLuca P, Rossetti RG, Alavian C, Karim P, Zurier RB. Effects of gammalinolenic acid on interleukin-1 beta and tumor necrosis factor-alpha secretion by stimulated human peripheral blood monocytes: studies in vitro and in vivo. Journal of Investigative Medicine. 1999;47(5):246–250.
    1. Ferrante A, Goh D, Harvey DP, et al. Neutrophil migration inhibitory properties of polyunsaturated fatty acids. The role of fatty acid structure, metabolism, and possible second messenger systems. Journal of Clinical Investigation. 1994;93(3):1063–1070.
    1. Serhan CN, Gotlinger K, Hong S, Arita M. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins and Other Lipid Mediators. 2004;73(3-4):155–172.
    1. Bordoni A, Di Nunzio M, Danesi F, Biagi PL. Polyunsaturated fatty acids: from diet to binding to ppars and other nuclear receptors. Genes & Nutrition. 2006;1:95–106.
    1. Feinstein DL, Galea E, Gavrilyuk V, et al. Peroxisome proliferator-activated receptor-γ agonists prevent experimental autoimmune encephalomyelitis. Annals of Neurology. 2002;51(6):694–702.
    1. Shinto L, Marracci G, Bumgarner L, Yadav V. The effects of omega-3 Fatty acids on matrix metalloproteinase-9 production and cell migration in human immune cells: implications for multiple sclerosis. Autoimmune Diseases. 2011;2011:6 pages.134592
    1. Van Horssen J, Witte ME, Schreibelt G, de Vries HE. Radical changes in multiple sclerosis pathogenesis. Biochimica et Biophysica Acta. 2011;1812(2):141–150.
    1. Lindquist S, Hassinger S, Lindquist JA, Sailer M. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment. Multiple Sclerosis. 2011;17(7):851–866.
    1. Bagasra O, Michaels FH, Zheng YM, et al. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(26):12041–12045.
    1. Johnson AW, Land JM, Thompson EJ, Bolanos JP, Clark JE, Heales JR. Evidence for increased nitric oxide production in multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry. 1995;58(1):p. 107.
    1. Yamashita T, Ando Y, Obayashi K, Uchino M, Ando M. Changes in nitrite and nitrate (NO2 −-/NO3 −) levels in cerebrospinal fluid of patients with multiple sclerosis. Journal of the Neurological Sciences. 1997;153(1):32–34.
    1. Giovannoni G, Heales SJR, Silver NC, et al. Raised serum nitrate and nitrite levels in patients with multiple sclerosis. Journal of the Neurological Sciences. 1997;145(1):77–81.
    1. Mirshafiey A, Mohsenzadegan M. Antioxidant therapy in multiple sclerosis. Immunopharmacology and Immunotoxicology. 2009;31(1):13–29.
    1. Cendrowski W. Multiple sclerosis and MaxEPA. British Journal of Clinical Practice. 1986;40(9):365–367.
    1. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurologica Scandinavica. 2000;102(3):143–149.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe